We are a pre-clinical drug development company focused on novel therapies to target kidney cancer.
Our mission is to translate innovative science into transformative cancer medicine.
We have developed a revolutionary small molecule with a dual mechanism of action of blocking the tumor driver, hypoxia-inducible factor (HIF)-2α and inducing cell death through excessive iron accumulation (ferroptosis).
The combination of ferroptosis induction + HIF-2α inhibition is a paradigm-shifting cancer treatment strategy with promising anti-tumor activity in animal models.
In 2018, Kuda Therapeutics was awarded a $300,000 SBIR Phase 1 grant from the National Cancer Institute to develop its novel anti-cancer therapeutics.
In 2020, Kuda Therapeutics received a $560,000 Idea Award from the Department of Defense to advance its ferroptosis inducer technology.
In 2022, Kuda Therapeutics was awarded a $2,050,000 SBIR Phase II grant from the National Cancer Institute to advance this technology towards FDA Investigational New Drug (IND) filing for human proof-of-concept studies.